Status:
COMPLETED
Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults
Lead Sponsor:
Environmental Protection Agency (EPA)
Conditions:
Exposure to Pollution
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Purpose: To determine whether exposure to levels of fine particles that are close to the current standard will cause cardiovascular changes in healthy individuals.
Detailed Description
Air pollution is associated with several adverse health outcomes. Specifically, ambient fine particulate matter ≤2.5 μg/m3 (PM2.5) is associated with increased mortality and increased risk for respira...
Eligibility Criteria
Inclusion
- Healthy individuals ages 18-35 years of age
- Physical conditioning allowing intermittent, moderate exercise for four hours. Ability to complete the exposure exercise regimen without reaching 80% of predicted maximal heart rate. Predicted maximal heart rate will be calculated using the equation (described by Tanaka et al.: \[2001\] J. Am. Coll. Cardiol.): \[208bpm-((0.7) x (age in years))\]
- Normal baseline 12-lead EKG .
- Normal lung function
- Forced vital capacity (FVC) ≥ 80% of that predicted for gender, ethnicity, age and height (according to NHANESIII guidelines).
- Forced expiratory volume in one second (FEV1) ≥ 80%of that predicted for gender,ethnicity, age and height
- FEV1) /FVC ratio≥ 80% of predicted values.
- Oxygen saturation ≥ 96% on room air.
Exclusion
- Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic diseases, or immunodeficiency state.
- Individuals with a CVD risk score greater than 10% using the ACC/AHA ASCVD risk calculator.
- Individuals with clinically diagnosed asthma.
- Individuals who are allergic to chemical vapors or gases.
- Females who are pregnant, attempting to become pregnant, or breastfeeding.
- Individuals that are unable or unwilling to stop for at least two weeks prior to the study taking medications, vitamins or supplements that the investigators believe may impact the results of the study. Those not specifically mentioned here may be reviewed by the investigators prior to an individual's inclusion in the study.
- Individuals who smoke/vape more than 2 times per month and have smoked/vaped within 4 weeks prior to all study visits.
- Individuals living with a smoker who smokes inside the house.
- Individuals with a body mass index (BMI) \>35 or \<18. Body mass index is calculated by dividing the weight in kilograms by the square of the height in meters.
- Individuals with occupational exposures to high levels of vapors, dust, gases, or fumes on an on-going basis.
- Individuals with uncontrolled hypertension (≥150 systolic or ≥90 diastolic).
- Individuals that do not understand or speak English.
- Individuals that are unable to perform the exercise required for the study.
- Individuals that are taking beta blocker medications.
- Individuals with a history of skin allergies to adhesives used in securing EKG electrodes.
- Individuals with unspecified diseases, conditions, or medications that might influence the responses to the exposures, as judged by the medical staff.
- Individuals that are unwilling or unable to stop taking over-the-counter pain medications such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), or other non-steroidal anti-inflammatory ("NSAID") medications for 48 hours prior to the exposures and post-exposure visits.
- Individuals that are taking systemic steroids or beta-blocker medications.
- Individuals with a hemoglobin A1c (HbA1c) level \> 6.4%.
- Temporary
Key Trial Info
Start Date :
January 16 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03232086
Start Date
January 16 2017
End Date
July 30 2020
Last Update
September 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.S. EPA Human Studies Facility
Chapel Hill, North Carolina, United States, 27514